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ABSTRACT 
 
Purpose 
This study evaluated in-house PCR testing for local identification of bacteria carrying the major 
carbapenemase genes (blaOXA-48-like, blaVIM, blaNDM, blaKPC and blaIMP). 
 
Methodology 
Carbapenemase-producing organisms (CPO) isolated from patients managed in two tertiary 
care hospitals in Scotland from September 2014–January 2017 were investigated. A 
combination of chromogenic screening agar (ChromID CARBA SMARTTM), a carbapenem 
hydrolysis test (Rapidec Carba NPTM) and in-house real-time PCR for the blaOXA-48-like, blaVIM, 
blaNDM, blaKPC and blaIMP genes were utilised. All isolates were sent to the AMRHAI reference 
unit for confirmatory testing.  
 
Results 
During the 29-month study period 39 CPO were isolated from 34 patients. The average 
turnaround time for a workflow involving phenotypic and molecular testing was 4.2 days. PCR 
had a sensitivity and specificity of 100%. The most common carbapenemase genes were 
blaOXA-48-like (31%), blaVIM (23%) and blaNDM (20%). Resistance to antimicrobials other than 
beta-lactams was common; the most active agents were colistin, amikacin and fosfomycin. 27 
patients were considered colonised (though CPO detection influenced empiric antimicrobials 
in five) and a CPO was implicated in infection in seven patients (bacteraemia in 
immunocompromised patients, n=2; surgical site infections, n=2; osteomyelitis in a patient 
with diabetes mellitus; and urinary tract infections, n=2). All patients survived infection.  
 
Conclusion 
In a low incidence setting we demonstrate the efficacy of a combined local laboratory workflow 
for rapid detection of CPO, incorporating phenotypic and molecular testing. In 7/34 patients 
the CPO was implicated as a pathogen and detection influenced antimicrobial decision-
making in 5 colonised patients. 
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INTRODUCTION 
 
Over the last decade, carbapenemase-producing organisms (CPO) have emerged as a major 
antimicrobial resistance concern. The frequent co-existence of resistance to additional 
antimicrobial classes can make management of CPO infections extremely challenging. 
Emphasising the clinical significance of these organisms is the observed association between 
carbapenem minimum inhibitory concentration (MIC) and mortality in Gram negative 
bacteraemia (1). The prevalence of CPO is highest in Southern Europe and Asia, but 
international travel has facilitated their global dissemination, with detection reported worldwide 
and the prevalence likely under-estimated due to a lack of systematic surveillance in many 
countries (2, 3). Although CPO detection is low in Scotland relative to the rest of the U.K. (61 
vs. 1893 isolates in 2015), surveillance data from the Public Health England Antimicrobial 
Resistance and Healthcare Associated Infections (AMRHAI) reference unit demonstrates a 
steady increase since 2003 (when there was a single isolate in Scotland), underscoring the 
need to develop diagnostic capabilities (4). 
 
Routine CPO screening in our institution is performed on patients who have been hospitalised 
outwith Scotland in the last 12-months, had contact with a CPO-colonised patient, or been 
previously colonised. If a CPO is detected in a clinical area then the other patients are 
screened weekly until the positive patient has been discharged. In addition, if a patient is 
admitted from another unit with a recent CPO then screening will also be performed. Screening 
utilises a rectal swab and/or faecal specimen, catheter urine if catheterised and wound 
swab/sputum if relevant. In high risk patients three negative screens are required to 
demonstrate negativity and allow stepping down of patient isolation and enhanced contact 
precautions. Current practice in our microbiology laboratory utilises phenotypic detection 
methods to detect CPO, with subsequent reference laboratory confirmation (Figure 1a).  
 
Molecular detection of carbapenemase genes performed locally, prior to testing by a 
regional/national reference laboratory, offers the advantage of rapid confirmation of CPO 
identity. The aims of this study were to (i) evaluate the use of in-house real-time multiplex PCR 
testing for identification of organisms carrying the major carbapenemase genes (blaOXA-48-like, 
blaVIM, blaNDM, blaKPC and blaIMP) as part of the local laboratory workflow and (ii) describe the 
clinical significance of CPO isolates detected at our institutions as part of laboratory, infection 
control and clinical quality improvement, using routinely gathered data. 
 
METHODS 
 
CPO isolates 
 
CPO isolated from patients managed in two tertiary care hospitals in Edinburgh, U.K., between 
September 2014–January 2017, were identified retrospectively. All isolates were also sent to 
AMRHAI for confirmation of carbapenemase status by MIC determination (agar dilution) and 
molecular testing. This was considered the ‘gold standard’ (5, 6). Organisms investigated for 
carbapenemase production (Figure 1a) were either identified from screening media (ChromID 
CARBA SMARTTM, Biomerieux) or from routine clinical specimens found by the Vitek2 
automated susceptibility testing analyser (Biomerieux) to have a raised carbapenem MIC 
(meropenem ≥0.5mg/L and/or ertapenem ≥1mg/L; the lowest possible result for both 
generated by the Vitek2). 
 
Laboratory workflow 
 
Isolates arising from routine susceptibility testing of clinical specimens were examined further 
by performing a meropenem E-test (Biomerieux) on Mueller-Hinton agar (Oxoid) and applying 
the same 0.5 McFarland standard inoculum to both halves of a chromID CARBA SMARTTM 
bi-plate. After 18-24 hours incubation in an aerobic atmosphere at 37ºC, any isolates either 
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growing on the screening agar and/or with a meropenem E-test MIC >0.125 mg/L (per 
EUCAST guidelines(7)) were further investigated by Rapidec Carba NPTM (Biomerieux) and 
in-house PCR. 
 
Isolates identified from growth on screening media were further examined by Rapidec Carba 
NPTM testing, a meropenem E-test and Vitek2 automated susceptibility testing. If the Vitek2 
meropenem MIC was ≥0.5mg/L, the meropenem E-test MIC was >0.125 mg/L or the Rapidec 
Carba NPTM was positive, then in-house PCR was performed. 
 
Phenotypic testing methods 
 
The ChromID CARBA SMARTTM bi-plate comprises one half specific for blaOXA-like producing 
organisms while the other half is specific for blaVIM, blaNDM, blaKPC and blaIMP producing 
organisms. The Rapidec Carba NPTM is a ready-to-use strip and employs the principles of the 
Carba NPTM test, a novel phenotypic carbapenem hydrolysis test (8) which relies on in vitro 
hydrolysis of a carbapenem by a bacterial lysate which is then detected by an alteration in pH 
using a phenol red indicator. The process including organism lysis and test incubation takes 
2.5 hours. 
 
Molecular testing methods 
 
Isolates were subjected to a simple boil extraction and then analysed by quadruplex real-
time PCR for blaOXA-48-like, blaVIM, blaNDM and blaKPC genes and monoplex real-time PCR for 
blaIMP (primer/probe sequences in Supplementary Table 1). These in-house PCRs were 
performed on the CFX Touch (BioRad) and results were analysed and interpreted using the 
BioRad CFX Manager software. The extraction process took 15 minutes and the PCR 
thermocycling component 2 hours. 
 
RESULTS 
 
Phenotypic and molecular detection of carbapenemase-producing organisms 
 
During the 29-month study period 81 isolates were investigated (Figure 1a) and 39 CPO were 
identified. The chromogenic CPO screening agar (ChromID CARBA SMARTTM) had a 
sensitivity of 97.4% and a specificity of 95.2% for detection of CPO (38/39 carbapenemase 
positive and 40/42 carbapenemase negative isolates were confirmed; the false negative result 
was a blaOXA-48-like-producing E. coli). 38/39 carbapenemase-positive and 41/42 
carbapenemase-negative isolates were confirmed using the Rapidec Carba NPTM test, giving 
a sensitivity of 97.4% and a specificity of 97.6% (the false negative result was a blaOXA-48-like-
producing E. coli). Two blaOXA-23-producing Acinetobacter baumannii and one blaIMI-producing 
Enterobacter cloacae were positive by Rapidec Carba NPTM and were characterised by 
AMRHAI. The sensitivity and specificity of the in-house multiplex real-time PCR was 100% 
and 100% (36/36 carbapenemase-positive isolates and 42/42 carbapenemase-negative 
isolates confirmed). Details of carbapenemase genes identified and organisms carrying these 
are shown in Figures 1b and 1c. The average turnaround time from specimen receipt to 
confirmation of CPO type was 4.2 days using the described workflow and 12.2 days if sent to 
the reference unit. 
 
Patient demographics 
 
The 39 CPO isolates were obtained from 34 different patients. 20/34 patients were male and 
the median age was 62 years (interquartile range 49-71). Seventeen patients were taking acid 
suppressing medication at the time of CPO isolation. Three patients had been re-patriated 
from hospitals abroad (Nigeria, India and South East Asia). A further five patients had recently 
travelled abroad (Turkey, n=2; India & China, n=1; India, n=2).  
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All blaIMP-carrying organisms were isolated from patients in the Haematology (n=4) or 
Oncology (n=1) wards, with no recent travel history. Four of these isolates underwent PFGE 
typing by the AMRHAI. Two were unique but two were identical and these came from two 
inpatients on the same ward during an overlapping time period, supporting patient-to-patient 
transmission (though not excluding a common environmental source). 
 
Of all 39 CPO isolates, 19 were detected from CPO screening specimens (during the study 
period 9057 screening specimens were examined) and 20 were first detected from a clinical 
specimen, Table 1. Of the 20 organisms isolated from clinical specimens, four were detected 
on a concomitant screen (performed in 16 cases). 
 
Carriage over time 
 
Subsequent specimens (screening or repeat clinical) were obtained in 21/39 patients and in 
17 cases did not identify a CPO. Of the 20 patients with a CPO initially identified from a clinical 
specimen, 12 had the specimen type repeated and in three cases (two, three and seven 
months later) the original CPO was still present. In the 19 patients with a CPO isolated from a 
screening specimen, nine had screening repeated afterwards, two of which were positive (1 
and 20 months later).  
 
Clinical significance 
 
In 22 patients, the isolation of a CPO was interpreted as colonisation and did not influence 
antimicrobial therapy. In five patients, the isolates were interpreted as colonisation but 
influenced empiric treatment of infection until additional microbiology results were available 
(n=3), empiric therapy of an infection with no diagnostic microbiology (n=1), and led to 
eradication therapy (urine colonisation) in one immunosuppressed patient.  
 
In seven patients the detection of a CPO was considered to represent infection and all of these 
organisms were identified from clinical specimens (details in Table 2).  
 
Antibiograms 
 
The complete antibiogram (derived from Vitek2 system or superseded by reference laboratory 
result in cases of disagreement) of CPO isolates from this study is presented in Figure 2. 
Across all isolates, the most active antimicrobials were colistin (95% susceptible), amikacin 
(74% susceptible), fosfomycin (74% susceptible) and tigecycline (63% susceptible). 
Ciprofloxacin and gentamicin did not have reliable activity (31% and 49% respectively).  
 
DISCUSSION 
 
Three carbapenemase detection methods were utilised in this study: chromogenic screening 
agar, a carbapenem hydrolysis test and in-house real-time PCR for the blaOXA-48-like, blaVIM, 
blaNDM, blaKPC and blaIMP genes. All methods had sensitivities of 97.4% to 100% and 
specificities of 95.2% to 100%, with PCR achieving 100% for both. The importance of including 
the carbapenem hydrolysis test is underscored by the detection of two blaOXA-23-carrying 
isolates and a blaIMI-carrying isolate as these targets were not included in the PCR panel, 
highlighting an inherent limitation to targeted PCR. The validated in-house PCR for the ‘Big 5’ 
carbapenemase genes is now included in our local laboratory portfolio for carbapenemase 
detection and we contend that there is an important role for locally performed PCR for 
detection/exclusion of CPO. This will enable early initiation of appropriate infection control 
measures and clinical decisions in the case of a positive result and for infection control 
measures to be de-escalated and side rooms released in the case of negative results. We 
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also recognise the emerging role for new immunochromatographic lateral flow assays as rapid 
diagnostic tests for identification of carbapenemase enzymes (9). 
 
For carbapenemase screening, EUCAST recommend using a meropenem MIC cut-off of 
>0.125mg/L. In this study, further CPO investigations were performed on routine clinical 
specimens if the Vitek2 meropenem MIC was ≥0.5mg/L, the lowest possible value for this 
system. Since this MIC cut-off is higher than the EUCAST recommendation, the screening 
step of our workflow may under-detect carbapenemase production by clinical isolates. 
 
34 patients had a CPO identified from a screening or clinical specimen. Interestingly, a low 
proportion of CPO isolated from clinical specimens were detected on a concomitant screening 
specimen (4/16). Recognised risk factors of travel to/hospitalisation in high CPO prevalence 
countries and proton pump inhibitor usage were common (10). PFGE typing indicates a 
possible nosocomial transmission event may have occurred between two patients. 
 
Seven patients had infection involving a CPO with no infection related deaths and combination 
therapy used in 3/7 cases (Table 2). The clinical outcomes for patients in our small case series 
differ from results of a pooled analysis of 692 patients with carbapenemase-producing 
Enterobacteriaceae infection published in 2014 (11). This large cohort was heterogeneous in 
terms of host immune status, organism and resistance gene (though K. pneumoniae was 
commonest), presence of bacteraemia and requirement for intensive care unit admission. 
Various mortality outcomes were reported (including in-hospital, 30-day, infection-related), 
with values of up to 80% in some studies, with benefit of combination therapy over 
monotherapy in critically ill patients with bacteraemia. 
 
In summary, in a low incidence Scottish setting we demonstrate the efficacy of a combined 
laboratory workflow for local detection of CPO, incorporating chromogenic screening agar, a 
carbapenem hydrolysis test and PCR assay for the blaOXA-48-like, blaVIM, blaNDM, blaKPC and blaIMP 
genes. Screening and clinical specimens contributed almost equally to the 39 CPO isolates 
identified over the 29-month study period. In seven cases the CPO was implicated in causing 
infection. 
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Figure 1: Laboratory methods and carbapenemase-producing organisms identified 
a Flowchart illustrating laboratory workflow. 
b Carbapenemase genes identified. blaIMI and blaOXA-23 genes determined by the reference laboratory 
(AMRHAI, Colindale). 
c Organisms carrying carbapenemase genes 
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Figure 2: Antibiogram of carbapenemase producing organisms 
 
S: sensitive; R: resistant; I: intermediate; grey box: not tested 
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Table 1: Sample type from which CPO identified 
 
Specimen type Number of CPO isolates 
CPO screening 
specimen* 
19 
Clinical specimen 20 
Urine 11 
Wound swab 3 
Tissue sample 1 
Sputum 3 
Blood culture 2 
 
Result of concomitant CPO screen if 
organism first detected on clinical 
specimen: 
Positive 4 
Negative 12 
Not done 4 
In 4 cases a CPO was identified from both a screening and clinical specimen. 
* A total of 9057 screening specimens were examined during the study period. 
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Table 2: Clinical characteristics of cases where CPO detection represented infection (not colonisation) 
 
Organism 
(gene) Relevant medical history CPO infection details 
CPO 
identification 
specimen 
CPO 
screen 
result 
Antimicrobial therapy Outcome 
E. cloacae 
(blaIMI) 
Metastatic breast cancer, receiving 
carboplatin and paclitaxel 
chemotherapy 
Concurrent S. aureus 
(MSSA) and E. cloacae 
bacteraemia 
Blood culture Negative Flucloxacillin and temocillin Survived 
E. cloacae 
(blaVIM) 
Gastric lymphoma, receiving R-
CHOP chemotherapy. Recent 
neutropenic sepsis managed with 
piperacillin-tazobactam and 
gentamicin. 
Bacteraemia Blood culture Negative Ciprofloxacin and gentamicin Survived 
E. cloacae 
(blaVIM) Back pain 
Vertebrectomy surgical 
site infection Wound swab Positive Co-trimoxazole Survived 
E. cloacae 
(blaVIM) Resected low grade glioma. 
Craniotomy surgical site 
infection with intra-
cerebral collections 
(blood & CNS sterile) 
Wound swab Negative Co-trimoxazole, meropenem and gentamicin Survived 
E. cloacae 
(blaKPC) 
Type 1 diabetes mellitus. Diabetic 
foot ulcer with underlying 
osteomyelitis. 
Osteomyelitis and 
subsequent infected 
amputation site 
Amputation 
tissue sample Negative 
Piperacillin-tazobactam, amikacin 
and colistin. Survived 
E. cloacae 
(blaVIM) 
Initially admitted with intra-
abdominal sepsis, successfully 
managed with piperacillin-
tazobactam. 
Nosocomial urinary tract 
infection Urine Negative Trimethoprim Survived 
E. coli 
(blaOXA-48-like) None 
Urinary tract infection 
with sepsis Urine Negative Ciprofloxacin Survived 
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SUPPLEMENTARY DATA 
 
Supplementary table 1: Primer and probe sequences used for detection of carbapenemase genes  
Gene Sequence 5’ – 3’ Concentration (µM) 
OXA-48-
like 
F ATGCGTGTATTAGCCTTA 5 
R TGAGCATTCCAACTTTTG 5 
P CY5-CTACCGCAGGCATTCCGATAAT 2 
KPC 
F TGCAGAGCCCAGTGTCAGTTT 6 
R CGCTCTATCGGCGATACCA 6 
P FAM- TTCCGTCACGGCGCGCG 4 
NDM 
F CCTGATCAAGGACAGCAA 5 
R TGGCTCATCACGATCATG 5 
P YAK-CCAAGTCGCTCGGCAATCTC 3 
VIM 
F1 GAGATTCCCACGCACTCTCTAGA 5 
F2 GAGATTCCCACGCATTCTCTAGA 5 
R AATGCGCAGCACCAGGATAG 5 
P TXR-ACGCAGTGCGCTTCGGTCCAGT 2 
IMP 
F GGCGGAATAGAGTGGCTTAATTCTC 10 
R1 GAATTTTTAGCTTGTACTTTACCGTCTTT 5 
R2 ATTTTTAGCTTGTACCTTACCGTATT 5 
R3 TTTGTAGCTTGCACCTTATTGTCTTT 10 
P FAM-ATGCATCTGAATTAAC-MGB 2 
F: forward; R: reverse; P: probe 
 
 
 
 
